A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Company Overview Lexaria Bioscience Corp. is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) using our patented DehydraTECHTM drug delivery technology. DehydraTECH combines APIs with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. DehydraTECH can be used with a wide range of active molecules including glucagon-like peptide-1 drugs (“GLP-1”) and glucose-dependent insulinotropic polypeptide drugs (“GIP”), vitamins, pain medications, hormones, antivirals, nicotine and its analogs, and cannabinoids. Our technology can be applied to a variety of therapeutic indications, including diabetes, weight loss, epilepsy, hypertension and heart disease.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 522K | - | - | - | - | - |
| Net Income | -11M | -12M | -5.8M | -6.7M | -7.3M | -4.0M |
| EPS | $-0.57 | $-0.66 | $-0.47 | $-1.01 | $-1.24 | $-0.95 |
| Free Cash Flow | -8.7M | -10M | -5.0M | -5.9M | -4.9M | -4.0M |
| ROIC | -1346.2% | -313.9% | -71.1% | -293.6% | -84.5% | - |
| Gross Margin | 100.0% | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.53 | 0.02 | 0.06 | - | - |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -11M | -12M | -5.8M | -6.5M | -6.6M | -5.7M |
| Operating Margin | -2062.0% | - | - | - | - | - |
| ROE | -219.7% | -215.9% | -72.1% | -218.9% | - | - |
| Shares Outstanding | 25M | 18M | 12M | 17M | 6M | 4M |
Lexaria Bioscience Corp. passes 0 of 9 quality checks, indicating weak fundamentals.
Lexaria Bioscience Corp. (LEXX) has a 5-year average return on invested capital (ROIC) of -77.8%. This is below average and may indicate limited pricing power.
Lexaria Bioscience Corp. (LEXX) has a market capitalization of $25M. It is classified as a small-cap stock.
Lexaria Bioscience Corp. (LEXX) does not currently pay a regular dividend.
Lexaria Bioscience Corp. (LEXX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Lexaria Bioscience Corp. (LEXX) generated $-10 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Lexaria Bioscience Corp. (LEXX) has a debt-to-equity ratio of 0.53. This indicates moderate leverage.
Lexaria Bioscience Corp. (LEXX) reported earnings per share (EPS) of $-0.66 in its most recent fiscal year.
Lexaria Bioscience Corp. (LEXX) has a return on equity (ROE) of -215.9%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 16 years of financial data for Lexaria Bioscience Corp. (LEXX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Lexaria Bioscience Corp. (LEXX) has a book value per share of $0.17, based on its most recent annual SEC filing.
No recent press releases.